Nurix Therapeutics, Inc. (NRIX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 11-30. Amounts in USD.

Revenue TTM

0 35M 70M 105M Q4 '19: 31.1M Q1 '20: 24.7M Q2 '20: 19.5M Q3 '20: 13M Q4 '20: 17.8M Q1 '21: 20M Q2 '21: 22.9M Q3 '21: 29M Q4 '21: 29.8M Q1 '22: 34.4M Q2 '22: 38.7M Q3 '22: 39.2M Q4 '22: 38.6M Q1 '23: 41.7M Q2 '23: 60.9M Q3 '23: 68.6M Q4 '23: 77M Q1 '24: 80.9M Q2 '24: 62.3M Q3 '24: 56.4M Q4 '24: 54.5M Q1 '25: 56.4M Q2 '25: 88.4M Q3 '25: 83.7M Q4 '25: 84M Q1 '26: 71.8M Q2 '26: 36.8M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-450M -300M -150M 0 150M 300M 450M Q2 '20: -42M Q3 '20: -58.5M Q4 '20: -65M Q1 '21: -77M Q2 '21: -90.1M Q3 '21: -99.9M Q4 '21: -117.9M Q1 '22: -136.1M Q2 '22: -155.4M Q3 '22: -173.1M Q4 '22: -183.9M Q1 '23: -184.1M Q2 '23: -165.1M Q3 '23: -158.4M Q4 '23: -155.1M Q1 '24: -157.3M Q2 '24: -179.1M Q3 '24: -193.7M Q4 '24: -213M Q1 '25: -230.7M Q2 '25: -230.5M Q3 '25: -267.2M Q4 '25: -285.7M Q1 '26: -315.3M Q2 '26: -361.2M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Net Income TTM

-450M -300M -150M 0 150M 300M 450M Q4 '19: -21.7M Q1 '20: -31.4M Q2 '20: -20.8M Q3 '20: -36.8M Q4 '20: -43.2M Q1 '21: -55.1M Q2 '21: -89.1M Q3 '21: -99.4M Q4 '21: -117.2M Q1 '22: -135.5M Q2 '22: -154.5M Q3 '22: -171.3M Q4 '22: -180.4M Q1 '23: -178.6M Q2 '23: -157.4M Q3 '23: -148.7M Q4 '23: -143.9M Q1 '24: -144.7M Q2 '24: -165M Q3 '24: -177M Q4 '24: -193.6M Q1 '25: -208.4M Q2 '25: -207.3M Q3 '25: -244.8M Q4 '25: -264.5M Q1 '26: -295.3M Q2 '26: -341.4M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-300M -200M -100M 0 100M 200M 300M Q4 '20: -80K Q1 '21: -33M Q2 '21: -50.1M Q3 '21: -73.9M Q4 '21: -84.4M Q1 '22: -135M Q2 '22: -136.4M Q3 '22: -152.8M Q4 '22: -159.8M Q1 '23: -165.6M Q2 '23: -151.2M Q3 '23: -146M Q4 '23: -81.4M Q1 '24: -74.9M Q2 '24: -96.1M Q3 '24: -97.1M Q4 '24: -172.6M Q1 '25: -191.7M Q2 '25: -215.2M Q3 '25: -230.4M Q4 '25: -249.5M Q1 '26: -260.3M Q2 '26: -293.7M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-450M -300M -150M 0 150M 300M 450M Q4 '20: -4.6M Q1 '21: -38M Q2 '21: -55.6M Q3 '21: -79.6M Q4 '21: -90M Q1 '22: -143.3M Q2 '22: -145.4M Q3 '22: -163.3M Q4 '22: -172.1M Q1 '23: -176.7M Q2 '23: -160.5M Q3 '23: -154.4M Q4 '23: -89.8M Q1 '24: -83.9M Q2 '24: -106M Q3 '24: -106.9M Q4 '24: -181.9M Q1 '25: -201.6M Q2 '25: -225.8M Q3 '25: -241.4M Q4 '25: -263.5M Q1 '26: -271.9M Q2 '26: -304.5M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 40M 80M 120M Q2 '20: 4.9M Q3 '20: 16.9M Q2 '21: 43.8M Q3 '21: 44.4M Q1 '22: 44.7M Q2 '22: 44.9M Q3 '22: 50.9M Q1 '23: 54M Q2 '23: 54.3M Q3 '23: 54.4M Q1 '24: 54.9M Q2 '24: 62.4M Q3 '24: 72.8M Q1 '25: 83.6M Q2 '25: 83.9M Q3 '25: 84.2M Q1 '26: 110.1M Q2 '26: 111.1M Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-9.00 -6.00 -3.00 0.00 3.00 6.00 9.00 Q4 '19: -5.94 Q1 '20: -8.60 Q2 '20: -7.71 Q3 '20: -8.14 Q4 '20: -5.10 Q1 '21: -2.23 Q2 '21: -2.83 Q3 '21: -2.39 Q4 '21: -2.73 Q1 '22: -3.05 Q2 '22: -3.46 Q3 '22: -3.71 Q4 '22: -3.72 Q1 '23: -3.52 Q2 '23: -2.96 Q3 '23: -2.74 Q4 '23: -2.65 Q1 '24: -2.66 Q2 '24: -2.92 Q3 '24: -2.91 Q4 '24: -2.89 Q1 '25: -2.80 Q2 '25: -2.61 Q3 '25: -2.97 Q4 '25: -3.05 Q1 '26: -3.17 Q2 '26: -3.46 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.